Related Experiment Video
Updated: Jul 9, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Aptamer Circuit-Engineered Bio-Nanovesicles With Self-Promoted Tumor-Targeting Loop for Efficient Immunogenic
Shuxuan Shao1, Cao Zhang1, Wei Du2
1Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing, FuRong Laboratory, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan, China.
Abstract:
Targeted delivery of chemodrugs to tumor sites is highly desirable for efficient chemotherapy. Extracellular vesicles (EVs)-based carrier is an ideal candidate for drug delivery in cancer therapy. However, the insufficient tumor-targeting capability remains to be solved. Herein, we designed an aptamer circuit with cascade recognition capacity to guide the vesicles for tumor targeting. The sequential signal transduction triggered by the specific binding between aptamers and their targets leads to the preferential binding of vesicles with cancerous cells rather than noncancerous cells with fewer targets. Moreover, a self-promoted tumor-targeting loop induced by Doxorubicin Hydrochloride (DOX) released from vesicles further amplified the targeting capability of the vesicle-based drug carrier to tumor sites through up-regulating PDL1 marker on the surface of tumor cells. Ultimately, the accumulation of DOX in tumor cells resulted in the immunogenic cell death (ICD) for evoking anti-tumor immune response. Overall, this work presents a self-promoted tumor-targeting strategy for vesicle-based carrier by coupling the cascade recognition and tumor-targeting loop, which improves the therapeutic effect of immunogenic chemotherapy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy

